THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$4.6M

Filings

Firms Hired

Active Period

2019–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$960,000	3	1
2025	$1,380,000	5	1
2024	$300,000	4	1
2023	$375,000	5	1
2022	$365,000	4	1
2021	$310,000	4	1
2020	$470,000	4	1
2019	$400,000	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	$4,560,000	34

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	33
SENATE	33
Health & Human Services, Dept of (HHS)	9
Food & Drug Administration (FDA)	5
Office of Science & Technology Policy (OSTP)	4
Office of Technology Policy (OTP)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medicare/Medicaid	Medicare/Medicaid	34
Budget/Appropriations	Budget/Appropriations	28
Law Enforcement/Crime/Criminal Justice	Law Enforcement/Crime/Criminal Justice	21
Health Issues	Health Issues	19
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	9
Government Issues	Government Issues	8
Science/Technology	Science/Technology	8
Education	Education	6
Pharmacy	Pharmacy	6
Immigration	Immigration	6

Bills Explicitly Cited (4)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3561118th Congress

PATIENT Act of 2023

2023 · third_quarter · Firm: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. H.R. 4473 Medicare Patient Access to Cancer Treatment; H.R. 3561 The PATIENT Act of 2023 H.R. 4822 Healthcare Price Transparency Act; S.1869 Site-based Invoicing and Transparency Enhancement

Client expense: $75,000 · Firm income: —

Matched citations: H.R. 3561

H.R. 4473118th Congress

Medicare Patient Access to Cancer Treatment Act

2023 · third_quarter · Firm: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. H.R. 4473 Medicare Patient Access to Cancer Treatment; H.R. 3561 The PATIENT Act of 2023 H.R. 4822 Healthcare Price Transparency Act; S.1869 Site-based Invoicing and Transparency Enhancement

Client expense: $75,000 · Firm income: —

Matched citations: H.R. 4473

H.R. 4822118th Congress

Health Care Price Transparency Act of 2023

2023 · third_quarter · Firm: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. H.R. 4473 Medicare Patient Access to Cancer Treatment; H.R. 3561 The PATIENT Act of 2023 H.R. 4822 Healthcare Price Transparency Act; S.1869 Site-based Invoicing and Transparency Enhancement

Client expense: $75,000 · Firm income: —

Matched citations: H.R. 4822

S. 1869118th Congress

SITE Act

2023 · third_quarter · Firm: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. H.R. 4473 Medicare Patient Access to Cancer Treatment; H.R. 3561 The PATIENT Act of 2023 H.R. 4822 Healthcare Price Transparency Act; S.1869 Site-based Invoicing and Transparency Enhancement

Client expense: $75,000 · Firm income: —

Matched citations: S.1869

Source: Senate LDA

THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER — Lobbying Disclosure | Poliscope